{"protocolSection": {"identificationModule": {"nctId": "NCT04848662", "orgStudyIdInfo": {"id": "AV006"}, "organization": {"fullName": "Bond Avillion 2 Development LP", "class": "INDUSTRY"}, "briefTitle": "To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.", "officialTitle": "A Phase I, Randomized, Open-label, Single-dose, 2-way Crossover Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 to Pulmicort Respules\u00ae in Children With Asthma Aged 4 to 8 Years (BLANC)", "acronym": "BLANC"}, "statusModule": {"statusVerifiedDate": "2022-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-05-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-07-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-07-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-04-01", "studyFirstSubmitQcDate": "2021-04-15", "studyFirstPostDateStruct": {"date": "2021-04-19", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-02-07", "resultsFirstSubmitQcDate": "2022-02-07", "resultsFirstPostDateStruct": {"date": "2022-04-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-04-12", "lastUpdatePostDateStruct": {"date": "2022-05-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bond Avillion 2 Development LP", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "A/B - Treatment with BDA MDI (PT027) 160/180 \u03bcg followed by treatment with Pulmicort Respules 1mg", "type": "EXPERIMENTAL", "description": "Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 \u03bcg at Visit 2, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3.", "interventionNames": ["Drug: BDA MDI (PT027) 160/180 \u03bcg", "Drug: Pulmicort Respules 0.5 MG/ML Inhalation Suspension"]}, {"label": "B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 \u03bcg", "type": "EXPERIMENTAL", "description": "Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 \u03bcg at Visit 3.", "interventionNames": ["Drug: BDA MDI (PT027) 160/180 \u03bcg", "Drug: Pulmicort Respules 0.5 MG/ML Inhalation Suspension"]}], "interventions": [{"type": "DRUG", "name": "BDA MDI (PT027) 160/180 \u03bcg", "description": "Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 \u03bcg per puff. Two puffs to administer 160/180 \u03bcg dose.", "armGroupLabels": ["A/B - Treatment with BDA MDI (PT027) 160/180 \u03bcg followed by treatment with Pulmicort Respules 1mg", "B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 \u03bcg"], "otherNames": ["PT027"]}, {"type": "DRUG", "name": "Pulmicort Respules 0.5 MG/ML Inhalation Suspension", "description": "Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.", "armGroupLabels": ["A/B - Treatment with BDA MDI (PT027) 160/180 \u03bcg followed by treatment with Pulmicort Respules 1mg", "B/A - Treatment with Pulmicort Respules 1 mg followed by treatment with BDA MDI (PT027) 160/180 \u03bcg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC0-t", "description": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing."}, {"measure": "Cmax", "description": "Maximum observed plasma concentration", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing."}], "secondaryOutcomes": [{"measure": "Tmax", "description": "Time to reach maximum observed plasma concentration", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing."}, {"measure": "Tlast", "description": "Time of last quantifiable plasma concentration", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing."}, {"measure": "Clast", "description": "Drug concentration at last observed (quantifiable) concentration", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures. Children should provide assent to join the study, as applicable. The child's parent(s) or legally authorized representative (LAR) must sign the informed consent form (ICF). The LAR must be aged \u226518 years old.\n2. Male or female aged between 4 and 8 years inclusive (not having reached his/her 9th birthday by the time of screening).\n3. Weigh at least 14 kg or higher.\n4. Clinician diagnosed asthma of at least 3 months.\n5. Stable on treatment with albuterol PRN and/or ICS and/or leukotriene receptor antagonists (LTRAs) for 2 weeks prior to screening; children taking budesonide in any form at Visit 1 will be switched to another corticosteroid with a washout of budesonide of 3 to 7 days.\n6. Demonstrate ability to correctly use the nebulizer and metered-dose inhaler (MDI) device without a spacer.\n7. Willingness and ability of the child and parent(s)/LAR to comply with the demands of the study as described in the informed consent/assent.\n\nExclusion Criteria:\n\n1. Inability to change from any budesonide therapy to another suitable corticosteroid.\n2. History of life-threatening asthma defined as any asthma episode associated with loss of consciousness, intubation or admission to an intensive care unit.\n3. Unstable asthma as judged by the Investigator (eg, any change in asthma therapy within 2 weeks prior to screening or use of more than 2 occasions of rescue medication (albuterol) per day within 1 week prior to screening (potential for rescreen).\n4. Children receiving regular maintenance treatment with prohibited anti-inflammatory or long-acting bronchodilator asthma medication (inhaled, nebulized, oral, or systemic) within 1 month prior to screening.\n5. More than 1 short course of oral/rectal/systemic corticosteroids within 6 months preceding screening (Visit 1), or any oral/rectal/systemic corticosteroids within 30 days prior to screening.\n6. Evidence of active concomitant pulmonary disease other than asthma (children with stable allergic rhinitis will be permitted, as long as, there are no changes in the treatment and the medications do not interfere with the analytical assay methods).\n7. Upper respiratory infection involving antibiotic treatment not resolved within 14 days prior to Visit 1.\n8. Children with a known or suspected hypersensitivity to albuterol/salbutamol, budesonide or any of the excipients used in the IMPs.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "8 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Frank Albers, MD, PhD", "affiliation": "Avillion LLP", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "IPS Research", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73106", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "TTS Research", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "No plans to share IPD"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The randomized treatment phase started after a screening period with a maximum duration of 14 days. Subjects who were taking budesonide in any form at Visit 1 were switched to another corticosteroid with a washout of budesonide of 3 to 7 days. In addition to the 12 subjects randomized, 1 subject was screened but did not participate (1 screen failure).", "recruitmentDetails": "The target population consisted of male or female children aged between 4 and 8 years who had clinician-diagnosed asthma of at least 3 months. Subjects were expected to be stable on treatment with albuterol as needed and/or inhaled corticosteroids and/or leukotriene receptor antagonists for 2 weeks prior to screening. The first subject enrolled on 06 May 2021 and the last subject completed the study on 08 July 2021. Subjects were enrolled at 2 US study centers.", "groups": [{"id": "FG000", "title": "A/B - Treatment With BDA MDI (PT027) 160/180 \u03bcg Followed by Treatment With Pulmicort Respules 1mg", "description": "Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 \u03bcg at Visit 2/Period 1, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3/Period 2.\n\nVisit 2/Period 1 (Day 1) - BDA MDI (PT027) 160/180 \u03bcg: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 \u03bcg per puff. Two puffs to administer 160/180 \u03bcg dose.\n\nVisit 3/Period 2 (Day 8 +/- 6 days) - Pulmicort Respules 0.5 mg/mL inhalation suspension: Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide."}, {"id": "FG001", "title": "B/A - Treatment With Pulmicort Respules 1 mg Followed by Treatment With BDA MDI (PT027) 160/180 \u03bcg", "description": "Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 \u03bcg at Visit 3.\n\nVisit 2/Period 1 (Day 1) - Pulmicort Respules 0.5 MG/ML Inhalation Suspension: Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.\n\nVisit 3/Period 2 (Day 8 +/- 6 days) - BDA MDI (PT027) 160/180 \u03bcg: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 \u03bcg per puff. Two puffs to administer 160/180 \u03bcg dose."}], "periods": [{"title": "Period 1 (First Treatment Intervention)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2 (Second Treatment Intervention)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "A/B - Treatment With BDA MDI (PT027) 160/180 \u03bcg Followed by Treatment With Pulmicort Respules 1mg", "description": "Subjects randomized to receive a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 \u03bcg at Visit 2/Period 1, and a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 3/Period 2.\n\nVisit 2/Period 1 (Day 1) - BDA MDI (PT027) 160/180 \u03bcg: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 \u03bcg per puff. Two puffs to administer 160/180 \u03bcg dose.\n\nVisit 3/Period 2 (Day 8 +/- 6 days) - Pulmicort Respules 0.5 mg/mL inhalation suspension: Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide."}, {"id": "BG001", "title": "B/A - Treatment With Pulmicort Respules 1 mg Followed by Treatment With BDA MDI (PT027) 160/180 \u03bcg", "description": "Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose inhaler, BDA MDI, (PT027) 160/180 \u03bcg at Visit 3.\n\nVisit 2/Period 1 (Day 1) - Pulmicort Respules 0.5 MG/ML Inhalation Suspension: Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.\n\nVisit 3/Period 2 (Day 8 +/- 6 days) - BDA MDI (PT027) 160/180 \u03bcg: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 \u03bcg per puff. Two puffs to administer 160/180 \u03bcg dose."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5.8", "spread": "1.72"}, {"groupId": "BG001", "value": "6.5", "spread": "1.64"}, {"groupId": "BG002", "value": "6.2", "spread": "1.64"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Age group (years)", "categories": [{"title": ">= 4 to < 6", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": ">= 6 to <9", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Centimeters (cm)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "118.22", "spread": "15.678"}, {"groupId": "BG001", "value": "123.42", "spread": "13.939"}, {"groupId": "BG002", "value": "120.82", "spread": "14.402"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms (kg)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.22", "spread": "10.270"}, {"groupId": "BG001", "value": "34.77", "spread": "12.430"}, {"groupId": "BG002", "value": "30.49", "spread": "11.752"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms per meter squared", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17.97", "spread": "2.641"}, {"groupId": "BG001", "value": "22.07", "spread": "3.269"}, {"groupId": "BG002", "value": "20.02", "spread": "3.551"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "AUC0-t", "description": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration", "populationDescription": "Budesonide PK samples were available from 12 children. There were 2 instances, one for each treatment intervention, where the pre-dose budesonide concentration was considered too high (16% and 46% of Cmax), potentially having an impact on the post-dose concentrations. There was also 1 instance in the Pulmicort Respules 1mg treatment intervention where post-dose samples were not collected due to difficulty with the catheter. PK parameters were not calculated in these three instances.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "h*pg/mL", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing.", "groups": [{"id": "OG000", "title": "Treatment Intervention - BDA MDI (PT027) 160/180 \u03bcg - All Subjects", "description": "Individual PK parameters and summary statistics after administration of study treatment A - BDA MDI (PT027) 160/180 \u03bcg"}, {"id": "OG001", "title": "Treatment Intervention B - Pulmicort Respules 1 mg", "description": "Individual PK parameters and summary statistics after administration of study treatment B - Pulmicort Respules 1mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "435", "spread": "191"}, {"groupId": "OG001", "value": "1164", "spread": "587"}]}]}]}, {"type": "PRIMARY", "title": "Cmax", "description": "Maximum observed plasma concentration", "populationDescription": "Budesonide PK samples were available from 12 children. There were 2 instances, one for each treatment intervention, where the pre-dose budesonide concentration was considered too high (16% and 46% of Cmax), potentially having an impact on the post-dose concentrations. There was also 1 instance in the Pulmicort Respules 1mg treatment intervention where post-dose samples were not collected due to difficulty with the catheter. PK parameters were not calculated in these three instances.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing.", "groups": [{"id": "OG000", "title": "Treatment Intervention - BDA MDI (PT027) 160/180 \u03bcg - All Subjects", "description": "Individual PK parameters and summary statistics after administration of study treatment A - BDA MDI (PT027) 160/180 \u03bcg"}, {"id": "OG001", "title": "Treatment Intervention B - Pulmicort Respules 1 mg", "description": "Individual PK parameters and summary statistics after administration of study treatment B - Pulmicort Respules 1mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "126", "spread": "53.3"}, {"groupId": "OG001", "value": "651", "spread": "480"}]}]}]}, {"type": "SECONDARY", "title": "Tmax", "description": "Time to reach maximum observed plasma concentration", "populationDescription": "Budesonide PK samples were available from 12 children. There were 2 instances, one for each treatment intervention, where the pre-dose budesonide concentration was considered too high (16% and 46% of Cmax), potentially having an impact on the post-dose concentrations. There was also 1 instance in the Pulmicort Respules 1mg treatment intervention where post-dose samples were not collected due to difficulty with the catheter. PK parameters were not calculated in these three instances.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing.", "groups": [{"id": "OG000", "title": "Treatment Intervention - BDA MDI (PT027) 160/180 \u03bcg - All Subjects", "description": "Individual PK parameters and summary statistics after administration of study treatment A - BDA MDI (PT027) 160/180 \u03bcg"}, {"id": "OG001", "title": "Treatment Intervention B - Pulmicort Respules 1 mg", "description": "Individual PK parameters and summary statistics after administration of study treatment B - Pulmicort Respules 1mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.667", "lowerLimit": "0.333", "upperLimit": "2.00"}, {"groupId": "OG001", "value": "0.167", "lowerLimit": "0.167", "upperLimit": "0.750"}]}]}]}, {"type": "SECONDARY", "title": "Tlast", "description": "Time of last quantifiable plasma concentration", "populationDescription": "Budesonide PK samples were available from 12 children. There were 2 instances, one for each treatment intervention, where the pre-dose budesonide concentration was considered too high (16% and 46% of Cmax), potentially having an impact on the post-dose concentrations. There was also 1 instance in the Pulmicort Respules 1mg treatment intervention where post-dose samples were not collected due to difficulty with the catheter. PK parameters were not calculated in these three instances.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing.", "groups": [{"id": "OG000", "title": "Treatment Intervention - BDA MDI (PT027) 160/180 \u03bcg - All Subjects", "description": "Individual PK parameters and summary statistics after administration of study treatment A - BDA MDI (PT027) 160/180 \u03bcg"}, {"id": "OG001", "title": "Treatment Intervention B - Pulmicort Respules 1 mg", "description": "Individual PK parameters and summary statistics after administration of study treatment B - Pulmicort Respules 1mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.0", "lowerLimit": "8.00", "upperLimit": "12.0"}, {"groupId": "OG001", "value": "12.0", "lowerLimit": "11.9", "upperLimit": "12.0"}]}]}]}, {"type": "SECONDARY", "title": "Clast", "description": "Drug concentration at last observed (quantifiable) concentration", "populationDescription": "Budesonide PK samples were available from 12 children. There were 2 instances, one for each treatment intervention, where the pre-dose budesonide concentration was considered too high (16% and 46% of Cmax), potentially having an impact on the post-dose concentrations. There was also 1 instance in the Pulmicort Respules 1mg treatment intervention where post-dose samples were not collected due to difficulty with the catheter. PK parameters were not calculated in these three instances.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "A total of 10 samples were taken per treatment visit at pre-dose and at 10, 20, 40, 60, 120, 240, 360, 480 and 720 minutes after dosing.", "groups": [{"id": "OG000", "title": "Treatment Intervention - BDA MDI (PT027) 160/180 \u03bcg - All Subjects", "description": "Individual PK parameters and summary statistics after administration of study treatment A - BDA MDI (PT027) 160/180 \u03bcg"}, {"id": "OG001", "title": "Treatment Intervention B - Pulmicort Respules 1 mg", "description": "Individual PK parameters and summary statistics after administration of study treatment B - Pulmicort Respules 1mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.5", "spread": "5.03"}, {"groupId": "OG001", "value": "18.7", "spread": "7.09"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Approximately one week for each treatment intervention.", "description": "Safety population included all subjects who received at least one treatment intervention.", "eventGroups": [{"id": "EG000", "title": "Treatment Intervention - BDA MDI (PT027) 160/180 \u03bcg - All Subjects", "description": "Safety analysis of subjects receiving Treatment A - BDA MDI (PT027) 160/180 \u03bcg", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 0, "otherNumAtRisk": 12}, {"id": "EG001", "title": "Treatment Intervention B - Pulmicort Respules 1 mg", "description": "Safety analysis of subjects receiving Treatment B - Pulmicort Respules 1mg", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 1, "otherNumAtRisk": 12}], "otherEvents": [{"term": "Miliaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 24.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "data or results obtained from this study must not be published without prior approval from the Sponsor."}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Avillion LLP", "email": "avillion@avillionllp.com", "phone": "+44 (0)203 764 9530"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-03-19", "uploadDate": "2022-02-07T05:02", "filename": "Prot_000.pdf", "size": 2519005}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2021-05-18", "uploadDate": "2022-02-07T05:04", "filename": "SAP_001.pdf", "size": 4289768}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Helicobacter", "relevance": "HIGH"}, {"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}]}}, "hasResults": true}